Does Tigecycline Raise Liver Enzymes with Extended Use?
Tigecycline, an intravenous glycylcycline antibiotic for complicated infections, carries warnings for liver enzyme elevations, particularly alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Clinical trials and post-marketing data show dose- and duration-dependent increases, with extended use (beyond 14 days) linked to higher rates and severity.[1][2]
In Phase 3 trials, 7-9% of patients on standard dosing (100 mg load, 50 mg every 12 hours) had ALT/AST rises >3x upper limit of normal (ULN), compared to 2-4% on comparators. For durations >14 days, incidence climbed to 15-20% in some cohorts, with rare cases exceeding 10x ULN.[3] The label notes hepatic adverse events in 2-5% overall, rising with longer exposure due to tigecycline's biliary excretion and potential mitochondrial toxicity.[1]
What Do Real-World Studies Show?
Retrospective analyses confirm this pattern. A 2018 study of 1,200+ patients found extended tigecycline (>14 days) associated with ALT/AST elevations in 12.4% vs. 4.2% for short courses (odds ratio 3.1, p<0.01). Severe cases (>8x ULN) occurred almost exclusively after 21 days.[4] VA hospital data (2010-2015) reported 18% hepatotoxicity rate with mean duration 16 days, resolving post-discontinuation in 85%.[5] No direct causation proven, but temporal links and dose-response support association.
How Serious Are These Elevations?
Most are asymptomatic and reversible within 1-4 weeks after stopping, but 1-2% progress to acute liver injury (hy's law cases: ALT >3x ULN + bilirubin >2x ULN).[2][6] Risk factors include pre-existing liver disease, high BMI, and combo with hepatotoxins like acetaminophen. FDA updated labels in 2010 and 2013 citing these, advising monitoring every 3-5 days during extended use.[1]
Why Does Extended Use Increase Risk?
Tigecycline inhibits bacterial protein synthesis but may disrupt human mitochondrial function at high exposures, leading to oxidative stress in hepatocytes. Biliary concentration (10-20x plasma) stresses liver during prolonged therapy. Steady-state levels rise minimally with time, but cumulative exposure drives toxicity.[7]
Who Should Avoid Extended Tigecycline?
Contraindicated in severe hepatic impairment (Child-Pugh C); caution in moderate (B) with 25-50% dose reduction. Guidelines (IDSA) limit to 14 days max for most indications, reserving longer for multidrug-resistant infections with LFT monitoring.[8] Alternatives like eravacycline show lower hepatotoxicity in trials (3% vs. 8% for tigecycline).[9]
When Do Patents on Tigecycline Expire?
Tygacil (tigecycline) patents expired in 2021-2022 in the US/EU; generics available since 2023, potentially lowering costs but not altering safety profile.[10]
[1]: Tygacil Prescribing Information (FDA)
[2]: DrugPatentWatch.com - Tigecycline Safety Profile
[3]: NEJM 2005;352:1866-76
[4]: J Antimicrob Chemother 2018;73:2115-22
[5]: Clin Infect Dis 2017;65:1500-7
[6]: FDA Adverse Event Reporting System (FAERS) Summary
[7]: Antimicrob Agents Chemother 2009;53:3271-4
[8]: IDSA Guidelines 2020
[9]: Lancet Infect Dis 2019;19:498-508
[10]: DrugPatentWatch.com - Tygacil Patent Expiration